Bypassing drug-resistance mechanisms of prostate cancer with small-molecules that target androgen receptor chromatin interactions

Human androgen receptor (AR) is a hormone-activated transcription factor that is an important drug-target in the treatment of prostate cancer. Current small molecule AR-antagonists, such as enzalutamide, compete with androgens that bind to the steroid binding pocket of the AR ligand binding domain (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Dalal, Kush, Che, Meixia, Que, Nanette S., Sharma, Aishwariya, Yang, Rendong, Lallous, Nada, Borgmann, Hendrik, Ozistanbullu, Deniz, Tse, Ronnie, Ban, Fuqiang, Li, Huifang, Tam, Kevin J., Roshan-Moniri, Mani, LeBlanc, Eric, Gleave, Martin E., Gewirth, Daniel T., Dehm, Scott M., Cherkasov, Artem, Rennie, Paul S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628141/
https://ncbi.nlm.nih.gov/pubmed/28775145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0259
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados